Rhumbline Advisers Verona Pharma PLC Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Verona Pharma PLC stock. As of the latest transaction made, Rhumbline Advisers holds 512 shares of VRNA stock, worth $54,737. This represents 0.0% of its overall portfolio holdings.
Number of Shares
512
Previous 562
8.9%
Holding current value
$54,737
Previous $35,000
37.14%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding VRNA
# of Institutions
322Shares Held
76.8MCall Options Held
977KPut Options Held
3.12M-
Janus Henderson Group PLC London, X06.13MShares$656 Million0.3% of portfolio
-
Perceptive Advisors LLC New York, NY5.51MShares$589 Million22.87% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y94.13MShares$441 Million16.48% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$362 Million16.88% of portfolio
-
Rtw Investments, LP New York, NY3.05MShares$326 Million4.43% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.52B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...